-

Arqit Quantum Inc. Investor News: Robbins LLP is Investigating Arqit Quantum Inc. (ARQQ) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Arqit Quantum Inc. (NASDAQ: ARQQ) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws by making false and misleading statements in its offering documents in support of its merger with Centricus Acquisition Corp (CENH). Arqit claims to be a cybersecurity company that has pioneered a unique quantum encryption technology.

If you would like more information about our investigation of Arqit Quantum Inc.'s misconduct, click here.

What is this Case About: According to the complaint filed against Arqit, in connection with the merger with Centricus, Arqit alleged its quantum encryption technology would be secure against current and future forms of cyberattacks, including from a quantum computer. Arqit also represented that it had "already signed major, long-term contracts for its services with large companies and government institutions."

However, defendants failed to disclose that Arqit’s proposed encryption technology would require widespread adoption of new protocols and standards for telecommunications, with British cybersecurity officials having questioned the viability of Arqit’s proposed encryption technology in a meeting in 2020. Further, the British government was not an Arqit customer but, rather, providing grants to Arqit, and Arqit had little more than an early-stage prototype of its encryption system at the time of the merger.

These facts became known on April 18, 2022, when The Wall Street Journal published an article titled, "British Encryption Startup Arqit Overstates Its Prospects, Former Staff and Others Say." On this news, Arqit share price fell $2.57 per share, or 17%, to close at $12.4 per share on April 18, 2022.

Next Steps: If you acquired shares of Arqit Quantum Inc. (ARQQ) f/k/a Centricus Acquisition Corp. between September 7, 2021 and April 18, 2022, or held Centricus securities and were entitled to vote on the merger, you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Arqit Quantum Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:ARQQ

Release Summary
Robbins LLP is Investigating Arqit Quantum Inc. (ARQQ) on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Erasca, Inc. Class Action Reminder - Robbins LLP Encourages ERAS Stockholders to Contact the Firm for Information About Their Rights  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. For more information...

VIA Transportation, Inc. Stock Drop: Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action Against VIA

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Via Transportation, Inc. (NYSE: VIA) in connection with the Company's September 15, 2025 initial public statement ("IPO"). Via Transportation, Inc. provides a platform that transforms global transportation systems into digital networks in the United States, Germany, and internationally.For more information, submit a form, email attorney Aaron D...
Back to Newsroom